NA
NAII.US Natural Alternatives International
- Market cap
- USD 6.08M
- P/E
- -
- P/B
- 0.12x
- ROE
- -21.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is NAII.US undervalued?
Graham numberThe Graham number of Natural Alternatives International cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Natural Alternatives International fundamental analysis
No fundamental analysis for Natural Alternatives International yet.
Natural Alternatives International stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Natural Alternatives International
Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States and internationally. The company operates through two segments: Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. It a…
Full company profileNatural Alternatives International financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Natural Alternatives International annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 122M | 132M | 138M | 119M | 179M | 171M | 154M | 114M | 130M | 143M | 112M |
| Gross Profit | 26.2M | 26.3M | 23.6M | 18.9M | 30.4M | 30.5M | 18.2M | 6.87M | 9.29M | 9.00M | 5.06M |
| Operating Income | 9.70M | 9.53M | 5.96M | -1.51M | 13.7M | 13.7M | 4.71M | -8.53M | -8.66M | -8.30M | -9.84M |
| EBITDA | 16.3M | 15.3M | 11.8M | 4.45M | 16.6M | 17.9M | 8.26M | -4.46M | -2.70M | -14.4M | -5.69M |
| Net Income | 7.24M | 5.05M | 6.54M | -1.65M | 10.8M | 10.7M | 2.52M | -7.22M | -13.6M | -20.7M | -9.92M |
| EPS | 1.09 | 0.73 | 0.92 | -0.25 | 1.69 | 1.74 | 0.43 | -1.23 | -2.28 | -3.43 | -1.63 |
| Balance Sheet | |||||||||||
| Total Assets | 72.6M | 85.2M | 93.5M | 120M | 120M | 146M | 134M | 162M | 152M | 126M | 115M |
| Total Liabilities | 11.5M | 17.0M | 17.4M | 48.8M | 40.2M | 57.5M | 45.4M | 79.7M | 83.5M | 76.5M | 67.3M |
| Shareholders' Equity | 61.1M | 68.2M | 76.1M | 71.4M | 80.1M | 88.5M | 88.8M | 82.6M | 68.4M | 50.0M | 47.2M |
| Cash & Short-term Investments | 27.8M | 23.6M | 25.0M | 30.5M | 32.1M | 21.8M | 13.6M | 12.0M | 12.3M | 7.39M | 6.49M |
| Total Debt | - | - | - | 28.8M | 16.5M | 31.8M | 30.9M | 60.3M | 59.0M | 50.0M | 30.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 14.1M | 1.83M | 6.56M | 3.69M | 20.8M | 11.9M | 7.02M | -1.50M | 5.93M | -8.92M | 4.78M |
| Capital Expenditure | 5.35M | 4.08M | 5.33M | 4.54M | 5.11M | 26.5M | 13.5M | 3.02M | 3.61M | 3.70M | 1.06M |
| Free Cash Flow | 8.78M | -2.25M | 1.24M | -850K | 15.7M | -14.6M | -6.51M | -4.51M | 2.32M | -12.6M | 3.73M |
| Ratios | |||||||||||
| ROE | 11.8% | 7.4% | 8.6% | -2.3% | 13.4% | 12.1% | 2.8% | -8.7% | -19.8% | -41.4% | -21.0% |
| ROA | 10.0% | 5.9% | 7.0% | -1.4% | 9.0% | 7.3% | 1.9% | -4.4% | -8.9% | -16.4% | -8.7% |
| Net Profit Margin | 5.9% | 3.8% | 4.7% | -1.4% | 6.0% | 6.3% | 1.6% | -6.3% | -10.5% | -14.5% | -8.8% |
| Debt to Equity | - | - | - | 0.40x | 0.21x | 0.36x | 0.35x | 0.73x | 0.86x | 1.00x | 0.65x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Natural Alternatives International dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 10.0M | 1.57 | 92.9% |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:50 on Jan 5, 1990.
Who owns Natural Alternatives International
- Insiders 21.42%
- Institutions 35.83%
- Public & others 42.74%
- Shares outstanding 6.26M
- Free float 4.88M
Top funds holding NAII.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 159K | 2.54% | 0.00% | Sep 2026 |
| DFA U.S. Small Cap Value I | 142K | 2.26% | 0.00% | Sep 2026 |
| DFA US Micro Cap I | 67.1K | 1.07% | 0.00% | Sep 2026 |
| DFA U.S. Small Cap I | 25.5K | 0.41% | 0.00% | Sep 2026 |
| EA Bridgeway Omni Small-Cap Value ETF | 24.9K | 0.40% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 21.0K | 0.34% | 0.00% | Sep 2026 |
| Bridgeway Omni Small-Cap Value N | 18.1K | 0.29% | 0.00% | Jun 2026 |
| Dimensional US Small Cap ETF | 16.9K | 0.27% | 0.00% | Oct 2026 |
| DFA U.S. Core Equity 2 Instl | 16.6K | 0.27% | 0.00% | Sep 2026 |
| DFA U.S. Core Equity 1 I | 10.3K | 0.16% | +5.96% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 8.48K | 0.14% | 0.00% | Oct 2026 |
| DFA U.S. Vector Equity I | 8.02K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 5.67K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 4.60K | 0.07% | 0.00% | Sep 2026 |
| DFA US Core Equity Class F | 4.34K | 0.07% | 0.00% | Aug 2026 |
| Fidelity Nasdaq Composite Index | 3.67K | 0.06% | 0.00% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 2.82K | 0.05% | 0.00% | Sep 2026 |
| DFA US Social Core Equity 2 Portfolio | 2.10K | 0.03% | 0.00% | Sep 2026 |
| Dimensional US Sm Company EUR Acc | 1.80K | 0.03% | -0.28% | Sep 2026 |
| Dimensional World Equity GBP Acc | 1.30K | 0.02% | -0.23% | Sep 2026 |
Top institutions holding NAII.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| CALDWELL SUTTER CAPITAL INC | 498K | 7.95% | -0.11% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 336K | 5.36% | 0.00% | Sep 2026 |
| Morgan Stanley - Brokerage Accounts | 308K | 4.91% | +14.68% | Jun 2026 |
| Mink Brook Asset Management LLC | 293K | 4.68% | -0.09% | Jun 2026 |
| Renaissance Technologies Corp | 256K | 4.08% | -7.79% | Sep 2026 |
| Vanguard Capital Management, LLC | 211K | 3.37% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 75.7K | 1.21% | +73.30% | Jun 2026 |
| Bridgeway Capital Management, LLC | 61.5K | 0.98% | -18.35% | Jun 2026 |
| Integrated Wealth Concepts LLC | 44.1K | 0.70% | +267.44% | Jun 2026 |
| Geode Capital Management, LLC | 43.7K | 0.70% | -16.59% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 27.1K | 0.43% | 0.00% | Jun 2026 |
| Empowered Funds, LLC | 24.9K | 0.40% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 19.9K | 0.32% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 17.6K | 0.28% | 0.00% | Jun 2026 |
| State Street Corp | 11.7K | 0.19% | 0.00% | Jun 2026 |
| James Investment Research, Inc. | 10.0K | 0.16% | 0.00% | Sep 2026 |
| Goss Wealth Management LLC | 10.0K | 0.16% | 0.00% | Jun 2026 |
| Vanguard Global Advisers, LLC | 2.82K | 0.05% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 2.03K | 0.03% | +82.70% | Jun 2026 |
| Mercer Global Advisors Inc. | 2.00K | 0.03% | 0.00% | Jun 2026 |
Natural Alternatives International company profile
- Company name
- Natural Alternatives International
- Ticker
- NAII.US
- Exchange
- USA Stocks
- Listed since
- Mar 13, 1987
- Sector
- Consumer Defensive
- Industry
- Personal Care Products
- Employees
- 301
- Fiscal year end
- June
- Address
- 1535 Faraday Avenue, Carlsbad, CA, United States, 92008
- Phone
- 760 736 7700
- Website
- nai-online.com
About Natural Alternatives International
Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States and internationally. The company operates through two segments: Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. It also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, and regulatory review. In addition, the company sells beta-alanine ingredients under the CarnoSyn, TriBsynm, CarnoSyn 4X, and SR CarnoSyn names. It manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. The company's private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer ecommerce channels, and retail stores. Natural Alternatives International, Inc. was founded in 1980 and is headquartered in Carlsbad, California.
Natural Alternatives International management
3- Mr. Mark A. LeDoux J.D.Chairman of the Board & CEO · born 1954
- Mr. Kenneth E. Wolf CPAPresident, COO, Secretary, Principal Financial & Principal Accounting Officer · born 1961
- Mr. Shane ContiVice President of Global Sales